GeneWeave BioSciences Raises $12M

genewaveGeneWeave BioSciences, a Los Gatos, Calif.-based clinical diagnostics company addressing multi-drug-resistant organisms (MDRO), raised $12m in funding.

The round was led by Decheng Capital with participation from existing investors Claremont Creek Ventures and XSeed Capital.

The company intends to use the funds for clinical studies and commercialization its technology.

Led by Steve Tablak, Chief Executive Officer, GeneWeave is an in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and determine the optimal antibiotic therapy for critical bacterial infections.



Join the discussion